Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis - Wikidata - wikimedia - TriplyDB

Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis

Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis

http://www.wikidata.org/entity/Q34621602

about

The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative Metabolism of antipyrine and sulphadimidine in dwarf goats: effects of the enzyme-inducing agents phenobarbital, troleandomycin and rifampicin.

P2860

Q34416893-ED9D6CA6-4C34-4B93-8187-B3F92C9EEECA Q34418061-55E5BB23-D7DB-42F8-9E32-3946C6ED1D8E Q35030873-2D4F0CDD-B619-4784-B465-B8F3ABDF4DCD Q41836161-214DBDC8-45EA-4399-B499-31B1F2164A72 Q46801997-46484BDD-34A6-40E1-B025-F4309F22ED3C

P2860

Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis

http://www.wikidata.org/entity/Q34621602

description

1984 nî lūn-bûn

@nan

1984 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1984 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1984年の論文

@ja

1984年論文

@yue

1984年論文

@zh-hant

1984年論文

@zh-hk

1984年論文

@zh-mo

1984年論文

@zh-tw

1984年论文

@wuu

name

Influence of rifampicin treatm ...... in patients with tuberculosis

@ast

Influence of rifampicin treatm ...... in patients with tuberculosis

@en

Influence of rifampicin treatm ...... in patients with tuberculosis

@nl

type

label

Influence of rifampicin treatm ...... in patients with tuberculosis

@ast

Influence of rifampicin treatm ...... in patients with tuberculosis

@en

Influence of rifampicin treatm ...... in patients with tuberculosis

@nl

prefLabel

Influence of rifampicin treatm ...... in patients with tuberculosis

@ast

Influence of rifampicin treatm ...... in patients with tuberculosis

@en

Influence of rifampicin treatm ...... in patients with tuberculosis

@nl

P1433

Q34621602-21C3A8D3-66D1-43E4-A0F0-E111E3E888B0

P1476

Q34621602-EBDDA9B2-9FF3-44F2-9A7C-3AFC856667F1

P2093

Q34621602-653B59CD-8AB7-4E81-9AE7-1509657D7F68

Q34621602-B8F789AA-4378-4B26-9DBA-74C1111617A6

Q34621602-CBEAA990-84E3-4B89-87C6-FAD0DF2AEAFC

Q34621602-D7A512E3-08F2-411B-9E2F-50B84A266B8F

P2860

Q34621602-09E0C2CD-79C1-48F3-994D-0E49A0513487

Q34621602-0B765A36-851B-4495-A855-D1B2016845C6

Q34621602-26B7B4D4-ACFD-4878-96A9-9F33262013B6

Q34621602-36886695-E789-4FAB-8972-30AC6710C604

Q34621602-3DB47DCA-CFC3-423A-B7D2-2ECE331417AF

Q34621602-4B28535F-A992-49EA-A113-FE70966B8C07

Q34621602-7FE3A6D8-6DE4-4D04-97CF-9078941FF265

Q34621602-82343D30-808F-40E1-B3C6-123897DE434C

Q34621602-96C60D82-4053-4FAC-89D5-EB863350C71E

Q34621602-B68BC95C-D242-43CF-95B7-B9E7E8595522

P304

Q34621602-C8284AC6-F911-4234-9DCA-F5F0123AD0E6

P31

Q34621602-7263BCB5-A619-4C0F-9260-FFCDEEDBD891

P356

Q34621602-3D01C3F6-CA30-4470-A211-CDBC68735388

P407

Q34621602-ABC81A73-56C3-4CA7-8512-E8A2A8C581EA

P433

Q34621602-1EE47CCB-102B-4627-BB69-EAF44E852CF3

P478

Q34621602-9D51537C-D313-4308-8C6A-208698DFF8FE

P577

Q34621602-6D1B7454-B6AD-439D-8C61-D40A448DEFD5

P5875

Q34621602-A447A1AB-FEDE-44A2-9662-ECAD8D70BA9E

P698

Q34621602-278DDA03-BC34-4E4C-96FD-5FE32D4DE1B7

P921

Q34621602-4AF10D62-D282-489A-ABBD-5E02551263A4

P932

Q34621602-492C2BB9-E0BC-42DA-A978-98756E6436F2

P356

J.1365-2125.1984.TB02532.X

P1433

British Journal of Clinical Pharmacology

P1476

Influence of rifampicin treatm ...... in patients with tuberculosis

@en

P2093

Bakker W

http://www.w3.org/2001/XMLSchema#string

Breimer DD

http://www.w3.org/2001/XMLSchema#string

Meerburg-Van der Torren JE

http://www.w3.org/2001/XMLSchema#string

Teunissen MW

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of rifampicin and isoniazid on vitamin D metabolism.

Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity.

Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine. A reconsideration of previously published data and synthesis of a pure reference substance.

Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Genetic and environmental factors affecting drug disposition in man.

Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.

Influence of cigarette smoking on drug metabolism in man.

Pharmacokinetic interactions with rifampicin.

Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

P304

701-706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.1984.TB02532.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

1984-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

16687286

http://www.w3.org/2001/XMLSchema#string

P698

6508979

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

1463547

http://www.w3.org/2001/XMLSchema#string